p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Jurnal Respirasi (JR)
Soedarsono Soedarsono
Sub-Pulmonology, Department of Internal Medicine, Faculty of Medicine, Hang Tuah University, Surabaya, Indonesia.

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

Change in Adenosine Deaminase Serum Levels from Before and Six Months After Treatment in Patients with Tuberculous Lymphadenopathy Christa Graziella Muljono; Soedarsono Soedarsono
Jurnal Respirasi Vol. 12 No. 1 (2026): January 2026
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jr.v12-I.1.2026.1-5

Abstract

Introduction: Tuberculous lymphadenopathy (TBLN) is challenging to both diagnose and treat. The outcome of a complete course of anti-tuberculosis (TB) drugs (ATDs) is evaluated based on clinical presentation and symptom improvement. Many clinicians administer ATDs for more than 6 months when they find residual lymphadenopathy or a paradoxical reaction. Therefore, this study assessed whether serum adenosine deaminase (ADA) levels are a suitable marker for evaluating the response to TBLN treatment and for analyzing changes in serum ADA levels from before to after 6 months of treatment with the standard ATD regimen in patients with TBLN. Methods: This prospective analytic observational study enrolled ATD-naïve patients with TBLN who received the standard 6-month ATD regimen in the TB directly observed therapy outpatient wards at Dr. Soetomo General Academic Hospital and Universitas Airlangga Hospital, Surabaya, from May 2023 to June 2024. Serum ADA levels were determined before and after treatment and compared using the Wilcoxon signed-rank test. Results: This study enrolled 22 patients, mostly female (n=14, 63.6%), with a mean age of 29.55±8.92 years old. The median serum ADA level was 18.7 (12.5-42.5) IU/L before and 13.9 (9.6-27.1) IU/L after treatment, with a significant mean decrease of -4.55 IU/L (p=0.001). Conclusion: Treatment with the standard 6-month ATD regimen decreased serum ADA levels in patients with TBLD. Therefore, serum ADA levels can be used as a follow-up test after treatment for patients with TBLN to evaluate their response to anti-TB therapy.
Potential Biomarkers and Inflammatory Modulation of Hyperbaric Oxygen Therapy in Long COVID: A Narrative Update Soedarsono Soedarsono; Rike Andy Wijaya; Verna Biutifasari
Jurnal Respirasi Vol. 12 No. 1 (2026): January 2026
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jr.v12-I.1.2026.90-96

Abstract

Introduction: Long coronavirus disease (COVID-19), also known as post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC), is characterized by persistent, often debilitating symptoms that extend beyond the acute phase of COVID-19. These manifestations are associated with immune dysregulation, chronic inflammation, and oxidative stress. Hyperbaric oxygen therapy (HBOT), which involves inhaling 100% oxygen at elevated atmospheric pressure, has emerged as a potential intervention to mitigate these processes. This narrative review synthesized findings from recent clinical and translational studies evaluating the immunological effects of HBOT in patients with long COVID. Methods: A structured search of PubMed, Scopus, and ScienceDirect was conducted for articles published between January 2020 and April 2025 using predefined keywords related to HBOT, long COVID, inflammation, and biomarkers. Seven primary studies met the inclusion criteria and were analyzed for their clinical outcomes and molecular immunomodulatory effects. Results: Evidence indicates that HBOT contributes to significant reductions in pro-inflammatory cytokines, such as interleukin (IL)-6 and tumor necrosis factor-α (TNF-α), while increasing anti-inflammatory cytokines, such as IL-10. Improvements in systemic biomarkers, including C-reactive protein, ferritin, and reactive oxygen species (ROS), have also been observed. In parallel, HBOT has been linked to enhanced mitochondrial function, immune balance, and tissue oxygenation, all of which support recovery from long COVID-related organ dysfunction. Conclusion: Despite promising results, heterogeneity in study design, small sample sizes, and limited long-term follow-up highlighted the need for further rigorous, standardized clinical trials. Overall, HBOT appears to be a biologically plausible and clinically relevant adjunctive therapy for long COVID, with inflammation-related biomarkers serving as correlates or secondary indicators of therapeutic response.